WineBusiness reports on an article by Dr Liz Thach MW that examines how GLP-1 weight-loss medications, such as Ozempic and Wegovy, affect wine consumption and enjoyment, challenging assumptions that they universally reduce demand. Two US consumer studies found that while many users drink less alcohol, 17% in one survey reported that wine tasted better, while 35% in another found wine more appealing and 49% reported no change. Researchers suggest that individual taste sensitivity, neurological changes and differences between medications may explain these findings, although further clinical research is needed. Crucially, some consumers are choosing to drink less frequently but purchase higher-quality wines, presenting opportunities for producers to focus on premiumisation, smaller formats and more considered drinking occasions. The article concludes that GLP-1 medications may reshape wine consumption rather than simply accelerate its decline, with potentially less damaging consequences for the industry than initially feared.